// App-Quantinova.ai

787 : DELTA-1: a global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

Researchers

Presenter

  • Brian Gastman

Principal Investigators

  • Donald Lawrence

  • Anthony Olszanski

  • Bartosz Chmielowski

  • Jose Lutzky

  • Marcus Butler

  • Omid Hamid

  • Pippa Corrie

  • Evidio Domingo-Musibay

  • Sajeve Thomas

  • Fiona Thistlethwaite

  • Gregory Daniels

  • Thomas Evans

  • Andrew Furness

  • Geoffrey Gibney

  • Mark Harries

  • Theresa Medina

  • Daniel Olson

  • Lalit Pallan

  • Eric Whitman

  • Melissa Wilson

  • Jeff Aycock

  • Robert Hawkins

  • Yizhou Jiang

  • Audrey Kennedy

  • Paul Robbins

  • Zachary Roberts

  • John Le Gall

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of California, Los Angeles, Los Angeles, CA

  • PRINCESS MARGARET CANCER CENTRE, Toronto, ON, Canada

  • Neurology, Medstar Georgetown University Hospital, Washington DC, DC

  • Royal Marsden NHS Foundation Trust, London, UK

  • Guys and St Thomas Hospitals NHS Foundation Trust, London, UK

  • Univeristy of Colorado, Denver, CO

  • Atlantic Health System, Morristown, NJ

  • University of Minnesota Masonic Cancer Research Center, Minneapolis, MN

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Univesity of Chicago, Chicago, USA

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Cleveland Clinic, Cleveland, OH

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • The Angeles Clinic & Research Institute, A Cedar-Sinai Affiliate, Los Angeles, CA

  • Moffitt Cancer Center, Tampa, FL

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Saint Luke's University Health Network, Easton, PA

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Orlando Health Heart Institute, Orlando, FL

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Interleukin-2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved